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Abstract 2 
Background: The P-wave duration (PWD) is an electrocardiographic (ECG) measurement that 3 
represents cardiac conduction in the atria. Shortened or prolonged PWD is associated with 4 
atrial fibrillation (AF). We used exome chip data to examine the associations between common 5 
and rare variants with PWD.  6 
Methods: Fifteen studies comprising 64,440 individuals (56,943 European, 5,681 African, 1,186 7 
Hispanic, 630 Asian), and ~230,000 variants were used to examine associations with maximum 8 
PWD across the 12-lead ECG. Meta-analyses summarized association results for common 9 
variants; gene-based burden and SKAT tests examined low-frequency variant-PWD associations. 10 
Additionally, we examined the associations between PWD loci and AF using previous AF GWAS.  11 
Results: We identified 21 common and low-frequency genetic loci (14 novel) associated with 12 
maximum PWD, including several AF loci (TTN, CAND2, SCN10A, PITX2, CAV1, SYNPO2L, SOX5, 13 
TBX5, MYH6, RPL3L). The top variants at known sarcomere genes (TTN, MYH6) were associated 14 
with longer PWD and increased AF risk. However, top variants at other loci (e.g., PITX2 and 15 
SCN10A) were associated with longer PWD but lower AF risk.  16 
Conclusion: Our results highlight multiple novel genetic loci associated with PWD, and 17 
underscore the shared mechanisms of atrial conduction and AF. Prolonged PWD may be an 18 
endophenotype for several different genetic mechanisms of AF.  19 
Keywords: Exome-chip analysis, P-wave duration, atrial fibrillation, cardiac conduction 20 
 21 
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 23 
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AF: atrial fibrillation 24 
cMAC: cumulative minor allele count 25 
GWAS: genome-wide association studies  26 
LV: left ventricle 27 
MAF minor allele frequency 28 
PWD: P-wave duration  29 
RAA: right atrial appendage  30 
SKAT: sequence kernel association test 31 
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P-wave duration (PWD) is an electrocardiographic measurement that reflects cardiac 32 
conduction through the atria. PWD variability may implicate intrinsic or acquired properties in 33 
the function and structure of atrial conductivity.1 Shortened and prolonged PWD have been 34 
repeatedly associated with atrial fibrillation (AF),2, 3 a common and heritable4 arrhythmia that 35 
predisposes to stroke, heart failure, and increased mortality.5-7 36 
Although PWD is heritable8, 9 only two genome-wide association studies (GWAS) have 37 
been conducted.10, 11 Given the relationship between PWD and AF, examining the genetic 38 
determinants of PWD may provide insights into the pathophysiology of AF. Moreover, 39 
assessment of coding variation may facilitate identification of AF-specific genes. Therefore, we 40 




Each study was reviewed and approved by the local or institutional IRB, and each participant 45 
provided consent. Study-specific details are provided in Supplemental Material, under 46 
“Description of participating studies” and in Supplemental Table 1.  In our primary analysis, we 47 
considered loci/genes significantly associated with PWD if a common variant (minor allele 48 
frequency [MAF] ≥ 5%) or a gene-based test, including burden or sequence kernel association 49 
test [SKAT]12 comprising low-frequency variants [MAF < 5% or MAF <1%]) exceeded exome-50 
wide significance in meta-analyses, after Bonferroni correction. We reported low-frequency 51 
variants that exceeded exome-wide significance at significant loci identified in gene-based 52 
analyses. The full Methods section is available in the Supplemental Material (under 53 
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“Methods”). Data supporting the findings of this study can be made available, following 54 
reasonable request to the corresponding author. 55 
 56 
Results 57 
A total of 64,440 individuals from 4 ethnic groups (56,943 European, 5,681 African, 630 Asian, 58 
1,186 Hispanic) and 15 studies were included in our meta-analysis. The per-study mean age 59 
ranged from 46.2-72.6 years; roughly 60% of participants were women (Table 1). For the multi-60 
ethnic single variant analyses, we tested ~26,000 common variants (see Supplemental Table 3 61 
for the exact number of variants included in each analysis). The Quantile-Quantile plots show a 62 
small degree of inflation for both PWD residuals (λ=1.10) and inverse normal transformed PWD 63 
residuals (λ=1.13; Supplemental Figures 1a-1b). We performed meta-analyses in ethnicity-64 
specific groups (European: λ=1.10-1.13; African: λ=1.03; Supplemental Figures 1c-1f). LD score 65 
regression intercepts were 1 (multi-ethnic analyses) and 0.95 (European-specific analyses), 66 
suggesting the inflation was mainly due to polygenicity. Meta-analysis results from PWD 67 
residuals, and inverse normal transformed PWD residuals were highly correlated across 68 
analyses (Pearson’s rho≥0.99, P<2.2×10-16; Supplemental Figure 2).  69 
 70 
Common variant analyses 71 
We identified 41 exome-wide significant variants at 18 loci (P-value <1.9×10-6; Supplemental 72 
Figure 3) in our multi-ethnic meta-analysis of PWD residuals (Table 2). Eleven of the 18 PWD 73 
loci are novel, representing the following nearest genes: PKP1 (rs1626370, P=2×10-6), TTN 74 
(rs2042995, P=4×10-7), PITX2 (rs17042171, P=8×10-11), ARHGAP10 (rs6845865, P=2×10-10), 75 
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TCF21 (rs2327429, P=2×10-7), CDK6 (rs2282978, P=2×10-8), SYNPO2L (rs3812629, P=4×10-7), 76 
SOX5 (rs17287293, P=3×10-7), HMGA2 (rs8756, P=7×10-7), GORS4 (rs17608766, P=9×10-15), and 77 
MC4R (rs12970134, P=1×10-6). Another novel locus was associated only with the inverse normal 78 
transformed PWD (JAZF1, P=1×10-6; Table 2; Supplemental Table 4). The PWD variance 79 
explained by each of the top variants ranged from 0.04% to 0.44%; the top variants in 80 
aggregate explained ~1.6% of the phenotypic variance. Associations for SCN10A and PITX2 81 
regions were moderately heterogeneous across individual studies (I2 ≥45%; Table 2). Of these 82 
19 multi-ethnic significantly associated loci, 13 were significantly associated with PWD residuals 83 
in the European ancestry subset, and one (SCN10A) was observed in individuals of African 84 
ancestry (Supplemental Table 4). No additional loci were observed in analyses restricted to 85 
either European or African ancestry (Supplemental Figure 4 for Manhattan plots). 86 
In conditional analyses, we identified additional signals from SCN5A and SCN10A 87 
(Supplemental Table 5). For inverse normal transformed PWD residuals, an additional signal 88 
(rs10033464, P-value=2×10-7) was observed in the PITX2 region. In addition to the 7 previously 89 
known loci that exceeded exome-wide significance, we observed 2 nominally significant 90 
associations with PWD at SSBP3 and EPAS1 (P <0.001; Supplemental Table 6).10 91 
 92 
Gene-based analyses 93 
We performed burden and SKAT tests for associations with PWD for 16,949 genes with a 94 
cumulative minor allele count (cMAC) ≥10, including 192,455 low-frequency and rare variants, 95 
in the multi-ethnic sample. We identified 4 genes associated with PWD using SKAT tests 96 
aggregating functional variants with MAF <5% (TTN, P=6×10-27; DLEC1, P=2×10-13; SCN10A, 97 
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P=7×10-8; and RPL3L, P=9×10-7; Table 3). We identified an additional association (TTC21A, 98 
P=1×10-6) using inverse normal transformed PWD residuals in the European-specific analysis. 99 
Using burden tests, we identified TTN and MUC5B as PWD-associated genes in the multi-ethnic 100 
and European-specific analyses. We did not observe any significant associations for variants 101 
with MAF <1%, suggesting that identified associations were mainly driven by low-frequency, 102 
not rare, variants. Among these significant genes, we identified two additional low-frequency 103 
missense variants exceeding exome-wide significance for association (DLEC1, rs116202356, 104 
Glu264Lys, P=2×10-10; RPL3L, rs113956264, Val262Met, P=1×10-6; Table 2), which were not 105 
reported in our single variant tests. 106 
 107 
eQTL analyses between genes at PWD loci and gene expression 108 
We assessed eQTL associations for top variants and proxies (linkage disequilibrium (LD): r2>0.8; 109 
1000 Genomes: phase 3 version 5, all individuals from LDlink13) in two heart tissues from GTEx 110 
version 7 (right atrial appendage (RAA) and left ventricle (LV); Supplemental Table 7).14 Six loci 111 
were associated with significant changes in gene expression, especially in the RAA, including 2 112 
known PWD loci (HCN1, FADS1) and 4 novel loci (TTN, TCF21, JAZF1, SYNPO2L) (Supplemental 113 
Table 7). The alleles associated with longer PWD at HCN1 and SYNPO2L had lower expression of 114 
these genes in RAA tissues. In contrast, alleles at the JAZF1 and FADS1 loci were associated with 115 
higher gene expression in the RAA and LV, respectively. Gene expression directionality was 116 
consistent across RAA and LV tissues. Expression level changes of JAZF1 and MYOZ1 per allele in 117 
RAA tissue were significantly higher than in the LV. We observed more significant eQTLs in the 118 
RAA than the LV, as expected, because P-wave duration reflects atrial conduction.  119 
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 120 
Relation of the PWD with ECG traits identifies 4 novel and 5 known loci 121 
We examined associations between PWD loci and other ECG measurements from large-scale 122 
association studies (Supplemental Table 8). We identified 8 novel (TTN, DLEC1, ARHGAP10, 123 
JAZF1, SYNPO2L, SOX5, HMGA2, GOSR2), and 5 known (SCN10A, CAV1, FADS1, TBX5, MYH6) 124 
PWD loci, all previously reported to be associated with PR interval, PR segment, QRS duration, 125 
QT interval, or RR interval.  Variants at TCF21, SYNPO2L, and MYH6 were associated with PR 126 
interval in recent large-scale genetic association studies,15-17 but the top variants in our PWD 127 
analysis were in low to moderate linkage disequilibrium with top variants from these earlier 128 
analyses (LD: r2 <0.8; 1000 Genomes: phase 3 version 5, all individuals) . 129 
  130 
Overlap between PWD loci and AF 131 
Fourteen PWD loci were associated with AF risk in a recent AF GWAS18 (P <0.0024=0.05/21 loci; 132 
Figure 1 and Supplemental Table 8). Two loci in well-known AF gene regions, PITX2 and TTN, 133 
were novel PWD loci. Among these 14 loci, 6 were associated with longer PWD and higher AF 134 
risk (TTN, TCF21, SOX5, GOSR2, MC4R, MYH6), whereas 8 were associated with longer PWD but 135 
lower AF risk (DLEC1, PITX2, CDK6, SYNPO2L, CAND2, SCN10A, CAV1, TBX5). 136 
 137 
Discussion 138 
In a multi-ancestry study comprising ~65,000 individuals, we identified 12 novel and 7 139 
previously reported loci related to PWD in a meta-analysis of common exome chip variants. 140 
After aggregating rare and low-frequency exonic variants, we identified 6 genes, including 2 141 
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additional low-frequency variants potentially related to PWD, and loci with specific patterns of 142 
association for PWD and AF risk. These findings suggest that AF may result from multiple 143 
genetic mechanisms, and PWD may be an endophenotype for these mechanisms.  144 
Our study extends the literature on the genetic components underlying atrial conduction, 145 
and the relationship between PWD and AF risk. In comparison to earlier genetic association 146 
studies of PWD,10, 11 we predominantly focused on genetic variants in coding regions (Table 2). 147 
In total, we identified 21 common variant loci related to PWD. The top common variants 148 
explain ~1.6% of the phenotypic variance in PWD. Our gene-based analyses also highlight the 149 
importance of low-frequency variants contributing to PWD in genes such as TTN, SCN10A, and 150 
RPL3L.  151 
Our findings have two major implications. First, associated loci span genes involved in the 152 
development and maintenance of adult cardiac tissue (PITX2, TCF21, HMGA2, NKX2-5, TBX5, 153 
CAND2, CDK6), muscle and sarcomere structure (TTN, SYNPO2L, SOX5, MYH6, RPL3L), ion 154 
channel function (HCN1, SCN10A), and cell-cell contact (PKP1, ARHGAP10, CAV1). We 155 
additionally noted several genes with a role in metabolism (JAZF1, CDK6, HMGA2, MC4R) 156 
though the connection to AF is less clear.19-22 The transcription factor PITX2 is the top 157 
susceptibility locus for AF. Decreased Pitx2 expression in the adult left atrium is associated with 158 
AF in humans,23 and abnormal cardiac conduction and low-voltage P-waves in knockout mice.24 159 
PITX2 is activated by TBX5 to co-regulate a number of membrane effector genes (such as 160 
SCN5A, GJA5 and RYR2). Reduction of Tbx5 expression in a mouse model decreased myocardial 161 
automaticity.25 TCF21 is a transcription factor required during embryogenesis for formation of 162 
heart tissue, and is involved in fibroblast generation after injury in adults.26 The nuclear 163 
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scaffolding protein HMGA2 trans-activates the heart specific transcription factor NKX2-5.27 164 
HMGA overexpression in mice mediates the response to pressure-overload induced cardiac 165 
remodeling.28 CAND2 suppresses myogenin degradation and directs cardiac progenitor cells 166 
towards a myocyte fate.29   167 
Titin (TTN) is a major structural component of the sarcomere, required for contractile 168 
function in cardiomyocytes. Loss of function mutations in TTN are associated with early-onset 169 
AF30 and dilated cardiomyopathy.31 Cytoskeletal Heart-enriched Actin-associated Protein 170 
(CHAP, aka SYNPO2L), is a Z-disc protein; zebrafish knockdown models display hypertrophy and 171 
delayed conduction,32 and the locus has been associated with AF in GWAS.18 SOX5 is a master 172 
regulator of cell fate in embryonic development.33 In drosophila, SOX5 knockdown results in 173 
decreased heart rate and increased cardiac wall thickness.34 MYH6, specifically expressed in the 174 
atria, forms the thick filament in cardiac smooth muscle; mutations are associated with 175 
cardiomyopathies,35 sinus node dysfunction,36 and congenital heart disease.37 Some identified 176 
genes are important for atrial conduction, including HCN138 and SCN10A39 which govern 177 
potassium, and late sodium channel currents, respectively. The proteins ARHGAP10,40 PKP1,41 178 
and CAV1,42 are involved in cell-cell contact and are necessary for efficient signal conduction. 179 
The ribosomal protein RPL3L is specifically expressed in skeletal muscle and heart; coding 180 
variants in this gene are associated with AF.43 181 
Second, our study implicates PWD as a powerful endophenotype for understanding the 182 
biological mechanisms of AF. Fifteen loci identified in our study were associated with AF risk in 183 
a recent AF GWAS,18 underscoring the genetic correlation between atrial conduction and AF 184 
risk. Epidemiological data indicate that PWD variability is associated with AF risk,2, 3 AF 185 
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recurrence after cardioversion44 and ablation,45 as well as ischemic stroke.46 Generally, we 186 
observed that top variants at known sarcomere genes (e.g., TTN, MYH6) were associated with 187 
increased PWD and increased AF risk, implicating atrial myopathic pathways in AF susceptibility. 188 
We speculate that myopathic pathways predispose individuals to AF via delayed conduction 189 
velocity, increased propensity for reentry, and susceptibility to ectopic atrial activity. Similarly, 190 
TCF21 and SOX5 are two transcription factors associated with increased PWD and increased AF 191 
risk. 192 
In contrast, top variants at SCN10A were associated with increased PWD but reduced AF 193 
risk. Other PWD-associated genes, such as PITX2, CAND2, TBX5, and CDK6, contained variants 194 
associated with longer PWD and reduced AF risk. The directionality of gene associations 195 
observed for PWD and AF risk underscore the complexity of AF susceptibility, while highlighting 196 
the potential to leverage PWD to elucidate AF-specific pathways (Figure 2). Whether studying 197 
PWD can lead to insights relevant for therapeutic targeting remains unclear.  198 
Our results should be interpreted within the context of our study design. First, the 199 
majority of our sample consisted of individuals of European ancestry and may have limited 200 
generalizability to non-European ancestries. Studies with broader ethnic/racial diversity are 201 
warranted. Second, top variants identified in our study may not directly modulate PWD, a 202 
limitation of most genetic association studies. Biological characterization of loci is needed to 203 
conclusively link variants to function. Third, ascertainment of rare variation is limited using the 204 
exome-chip, and future analyses of sequence data are warranted. Fourth, despite a relatively 205 
large sample, our findings explained a small proportion of phenotypic variance. Because the 206 
additive SNP-based heritability of PWD has been estimated to be as high as 19%,8 our results 207 
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highlight the fact that much of the genetic susceptibility to PWD remains unexplained. Larger 208 
samples, genome-wide assessments, and examination of rare variation may be necessary to 209 
identify additional loci for PWD. 210 
In conclusion, we identified 14 novel loci in common and low-frequency variant analyses 211 
and 6 gene regions in a low-frequency variant analysis for PWD. Our findings highlight the 212 
shared genetic components of atrial conduction and AF risk, and illustrate the diverse biological 213 
pathways affecting atrial conduction and mechanisms leading to AF.  214 
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Tables 403 
Table 1. Study participant characteristics* 404 











ARIC European 8861  53.9±5.7 54.1  106.0±11.8 920.5±133.8 
 
African 2922  53.3±5.8 62.2  111.5±11.9 924.2±148.6 
BRIGHT European 195 60.5±8.9 57.4 121.1±19.4 976.1±186.0 
CAMP European 1887 59.9±10.4 37.4 106.0±15.8 936.8±171.3 
CHS European 2648 72.3±5.4 60.7 109.9±13.0 950.0±145.8 
 
African 445 72.6±5.6 64.5 112.2±13.1 912.8±156.4 
ERF European 514 49.0±14.3 54.1 111.2±12.4 963.4±152.9 
FHS European 5677 47.2±13.3 55.0 105.0±12.0 973.7±155.9 
INTER99 European 5872 46.2±7.9 51.6 104.3±12.5 920.4±150.5 
KORA European 2435 47.1±12.8 51.9 108.0±11.1 939.7±147.7 
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LIFELINES European 1914 45.2±13.0 59.8 112.1±12.4 897.3±144.5 
UHP European 1657 38.5±12.5 55.8 109.1±14.6 956.5±152.4 
MESA European 2083 61.8±10.1 51.8 104.4±12.9 1054.5±158.9 
 
African 1131 61.3±10.3 52.9 107.9±12.3 1054.4±170.2 
 
Hispanic 1186 60.6±10.3 50.1 105.2±12.0 1061.0±154.5 
 
Asian 630 61.3±10.3 50.2 101.7±11.7  1059.0±140.3 
NEO European 5119 55.6±6.0 51.9 114.2±13.9 933.8±150.5 
RS European 1740 69.5±8.4 51.4 120.1±12.4 859.8±140.6 
SHIP-0 European 2653 46.5±15.4 51.8 109.5±11.2 853.6±147.8 
SHIP-Trend European 2922 47.9±14.6 52.5 113.1±11.9 911.3±134.5 
WHI European 10766 65.8±6.6 100 107.2±11.9 914.3±134.2 
  African 1183  64.3±6.5 100  110.6±11.5 920.2±143.7 
*N: sample size405 
406 
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Table 2. Top exome-wide significant variants for P-wave duration in multi-ethnic meta-analysis* 407 
        Residuals  Inverse normal transformed 
residuals 
Locus Closest gene Location rsID EA Function N EAF Beta SE P h2(%) I2(%
) 
 Beta SE P h2(%) I2(%) 
Novel loci 
  
      
1 PKP1 1q32.1 rs1626370 A missense 64431 0.2 0.39 0.08 2×10-6 0.04 2  0.03 0.01 2×10-6 0.04 0 
2 TTN† 2q31.2 rs2042995 C intron 64410 0.3 0.41 0.08 4×10-7 0.04 8  0.03 0.01 5×10-7 0.04 12 
3 DLEC1‡ 3p22.2 rs116202356 G missense 64331 0.98 1.72 0.27 2×10-10 0.06 20  0.14 0.02 2×10-10 0.06 19 
4 PITX2 4q25 rs17042171 C intergenic 64399 0.9 0.64 0.10 8×10-11 0.07 45  0.06 0.01 2×10-11 0.07 50 
5 ARHGAP10 4q31.23 rs6845865 C intron 64437 0.2 0.54 0.09 2×10-10 0.06 0  0.05 0.01 9×10-11 0.07 0 
6 TCF21/TARID 6q23.2 rs2327429 C upstream 64434 0.3 0.39 0.07 2×10-7 0.04 13  0.03 0.01 1×10-7 0.04 9 
7 JAZF1 7p15.1 rs864745 C intron 64388 0.5 0.32 0.07 2×10-6 0.04 0  0.03 0.01 1×10-6 0.04 0 
8 CDK6 7q21.2 rs2282978 C intron 64424 0.4 0.39 0.07 2×10-8 0.05 0  0.03 0.01 5×10-8 0.05 6 
9 SYNPO2L 10q22.2 rs3812629 A missense 64423 0.2 0.47 0.09 4×10-7 0.04 0  0.04 0.01 7×10-7 0.04 0 
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10 SOX5 12p12.1 rs17287293 A intergenic 64429 0.9 0.49 0.10 3×10-7 0.04 0  0.04 0.01 3×10-7 0.04 0 
11 HMGA2 12q14.3 rs8756 C 3‘-UTR 64418 0.5 0.33 0.07 7×10-7 0.04 0  0.03 0.01 5×10-7 0.04 0 
12 RPL3L‡ 16p13.3 rs113956264 C missense 64403 0.97 0.99 0.20 1×10-6 0.04 0  0.08 0.02 4×10-6 0.03 10 
13 GOSR2 17q21.32 rs17608766 C intron 64435 0.1 0.80 0.10 9×10-15 0.09 0  0.07 0.01 1×10-15 0.10 0 
14 MC4R 18q21.32 rs12970134 A intergenic 64430 0.3 0.38 0.08 1×10-6 0.04 0  0.03 0.01 7×10-6 0.03 0 
Previously reported loci            
15 CAND2 3p25.2 rs11718898 T missense 52472 0.3 0.39 0.08 9×10-7 0.05 0  0.03 0.01 8×10-7 0.05 0 
CAND2 3p25.2 rs3732675 T missense 64395 0.4 0.34 0.07 1×10-6 0.04 0  0.03 0.01 3×10-7 0.04 0 
16 SCN10A 3p22.2 rs6800541 C intron 64423 0.4 1.18 0.07 4×10-63 0.44 51  0.10 0.01 2×10-65 0.45 45 
17 HCN1 5p12 rs6892594 T intron 64427 0.4 0.43 0.07 2×10-10 0.06 0  0.04 0.01 3×10-10 0.06 0 
18 CAV1 7q31.2 rs3807989 A intron 64430 0.4 0.47 0.07 2×10-12 0.08 0  0.04 0.01 8×10-13 0.08 0 
19 FADS1 11q12.2 rs174546 C 3’-UTR 64430 0.7 0.50 0.07 2×10-11 0.07 9  0.04 0.01 6×10-12 0.07 9 
20 TBX5 12q24.21 rs883079 C 3’-UTR 64435 0.3 0.80 0.07 9×10-28 0.19 17  0.07 0.01 6×10-29 0.19 11 
21 MYH6 14q11.2 rs452036 A intron 64422 0.4 0.68 0.07 8×10-23 0.15 0  0.06 0.01 1×10-23 0.16 0 
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*EA: effect allele, N: sample size, EAF: effect allele frequency, Beta: the changes of (inverse normal transformed) P-wave duration 408 
residuals per 1 effect allele increment, SE: standard error, h2: SNP heritability estimate. P-values in bold are at exome-wide 409 
significance. 410 
†Locus with minor allele frequency <5% is also identified from gene-based analysis 411 
‡Locus with minor allele frequency <5% identified from gene-based analysis412 
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Table 3. Top gene in low frequency variant gene-based analyses of P-wave duration stratified by ancestral group.  413 
 





















Gene cMAC P† P cMAC P P cMAC P P 
SKAT             
TTN 775 276986 5×10-27 5×10-26 704 215801 5×10-27 1×10-26 536 23041 0.59 0.71 
DLEC1 57 10419 2×10-13 2×10-13 55 6937 2×10-12 3×10-12 39 2568 0.70 0.73 
TTC21A 37 12207 1×10-5 5×10-6 32 10900 4×10-6 1×10-6 28 1250 0.98 0.98 
SCN10A 61 16550 7×10-8 9×10-9 47 12804 2×10-7 4×10-8 34 524 0.84 0.81 
RPL3L 26 8510 1×10-6 4×10-6 25 6742 2×10-6 1×10-5 18 265 0.33 0.21 
Burden             
TTN 775 276986 1×10-14 8×10-14 704 215801 1×10-20 4×10-18 536 23041 0.26 0.27 
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MUC5B 68 36414 7×10-6 1×10-5 63 25110 3×10-6 6×10-6 58 2846 0.59 0.56 
Var#: number of variants included in the gene set, cMAC: cumulative minor allele count. 414 
P-values in bold exceed the exome-wide significance threshold (P-value <3.0×10-6, 3.1×10-6, and 3.5×10-6 for individuals of multi-415 
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Figure legends 421 
Figure 1. P-wave duration loci and atrial fibrillation risk. The x-axis represents the association 422 
between the top P-wave duration (PWD) loci and PWD in -log10 scale. The y-axis represents the 423 
association P-value between the top PWD loci and atrial fibrillation (AF) risk (-log10 scale). 424 
Variants above y=0 refer to loci associated with longer PWD and higher AF risk (colored in 425 
yellow). Variants below y=0 refer to loci associated with longer PWD but lower AF risk (colored 426 
in blue). Displayed results are from the multi-ethnic meta-analysis of PWD residuals. 427 
Associations with AF were derived from a recent AF GWAS.18 Dashed lines show the significance 428 
threshold for the current exome-wide analysis (vertical; P-value<1.9×10-6) and for prior 429 
genome-wide analyses of AF (horizontal; P-value<5×10-8). The dotted line represents the 430 
significance cutoff after Bonferroni correction (horizontal; P-value<2.4×10-3=0.05/21 PWD loci). 431 
 432 
Figure 2: Identified P-wave duration associated genes highlight multiple biological pathways 433 
for atrial fibrillation risk. Gene with increasing risk of AF coupled with prolonged PWD are 434 
listed at the right. Gene with decreasing risk of AF coupled with prolonged PWD are listed at the 435 
left. Each gene is accompanied by a diagram representing the biological function of the gene, 436 
indicating how the gene may affect PWD. 437 
438 
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Figure 2: Identified P-wave duration associated genes highlight multiple biological pathways 443 
for atrial fibrillation risk 444 
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